Europe small molecule API market was valued at $43.5 billion in 2022 and will grow by 7.4% annually over 2022-2032, driven by the increasing incidences of diseases, the development of high-potency small molecule APIs, patents expiry of the top-selling pharmaceuticals, the increasing technological developments in manufacturing sector, and a surging healthcare expenditure.
Highlighted with 70 tables and 52 figures, this 132-page report 鈥淓urope Small Molecule API 麻豆原创 2022-2032 by Source (Synthetic, Semi-synthetic, Natural), Product Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity鈥� is based on comprehensive research of the entire Europe small molecule API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe small molecule API market in every aspect of the classification from perspectives of Source, Product Type, Therapeutic Area, Application, Manufacturer Type, and Country.
Based on Source, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Synthetic API
o Branded Synthetic API
o Generic Synthetic API
鈥� Semi-synthetic API
鈥� Natural Origin
Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Standard API
鈥� High Potency API (HPAPI)
o Branded HPAPI
o Generic HPAPI
By Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Infectious Diseases
鈥� Oncology
鈥� Ophthalmology
鈥� Cardiovascular Disorders
鈥� Central Nervous System
鈥� Respiratory Disorders
鈥� Metabolic Diseases
鈥� Other Therapeutic Areas
By Application, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Clinical Use
鈥� Commercial Use
By Manufacturer Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Pharmaceutical Companies
鈥� CMOs
Geographically, the following national/local markets are fully investigated:
鈥� Germany
鈥� UK
鈥� France
鈥� Spain
鈥� Italy
鈥� Russia
鈥� Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Product Type, Therapeutic Area, and Manufacturer Type over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Aurobindo Pharma Ltd.
Cambrex Corporation
Catalent Inc.
Dr. Reddy's Laboratories
GlaxoSmithKline plc
Lonza Group
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Wuxi AppTec Co., Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of 麻豆原创 Research Methodology 12
1.2.2 麻豆原创 Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 麻豆原创 Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 麻豆原创 Overview and Dynamics 20
2.1 麻豆原创 Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the 麻豆原创 24
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 26
2.2 Major Growth Drivers 30
2.3 麻豆原创 Restraints and Challenges 34
2.4 Emerging Opportunities and 麻豆原创 Trends 37
2.5 Porter鈥檚 Fiver Forces Analysis 41
3 Segmentation of Europe 麻豆原创 by Source 45
3.1 麻豆原创 Overview by Source 45
3.2 Synthetic API 47
3.2.1 Branded Synthetic API 48
3.2.2 Generic Synthetic API 49
3.3 Semi-synthetic API 50
3.4 Natural Origin 51
4 Segmentation of Europe 麻豆原创 by Product Type 52
4.1 麻豆原创 Overview by Product Type 52
4.2 Standard API 54
4.3 High Potency API (HPAPI) 55
4.3.1 Branded HPAPI 56
4.3.2 Generic HPAPI 57
5 Segmentation of Europe 麻豆原创 by Therapeutic Area 58
5.1 麻豆原创 Overview by Therapeutic Area 58
5.2 Infectious Diseases 60
5.3 Oncology 61
5.4 Ophthalmology 62
5.5 Cardiovascular Disorders 63
5.6 Central Nervous System 64
5.7 Respiratory Disorders 65
5.8 Metabolic Diseases 66
5.9 Other Therapeutic Areas 67
6 Segmentation of Europe 麻豆原创 by Application 68
6.1 麻豆原创 Overview by Application 68
6.2 Clinical Use 70
6.3 Commercial Use 71
7 Segmentation of Europe 麻豆原创 by Manufacturer Type 72
7.1 麻豆原创 Overview by Manufacturer Type 72
7.2 Pharmaceutical Companies 74
7.3 CMOs 76
8 European 麻豆原创 2022-2032 by Country 78
8.1 Overview of European 麻豆原创 78
8.2 Germany 81
8.3 U.K. 83
8.4 France 85
8.5 Spain 87
8.6 Italy 89
8.7 Russia 91
8.8 Rest of European 麻豆原创 93
9 Competitive Landscape 95
9.1 Overview of Key Vendors 95
9.2 New Product Launch, Partnership, Investment, and M&A 98
9.3 Company Profiles 99
Aurobindo Pharma Ltd. 99
Cambrex Corporation 101
Catalent Inc. 102
Dr. Reddy's Laboratories 105
GlaxoSmithKline plc 108
Lonza Group 112
Merck & Co., Inc. 115
Mylan N.V. 117
Novartis AG 119
Pfizer Inc. 121
Sun Pharmaceutical Industries Ltd. 125
Teva Pharmaceutical Industries Ltd. 128
Wuxi AppTec Co., Ltd. 130
RELATED REPORTS 132
List of Tables:
Table 1. Snapshot of Europe Small Molecule API 麻豆原创 in Balanced Perspective, 2022-2032 18
Table 2. World Economic Outlook, 2021-2031 22
Table 3. World Economic Outlook, 2021-2023 23
Table 4. Scenarios for Economic Impact of Ukraine Crisis 27
Table 5. World Health Spending by Region, $ bn, 2013-2020 32
Table 6. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn 33
Table 7. Main Product Trends and 麻豆原创 Opportunities in Europe Small Molecule API 麻豆原创 37
Table 8. Europe Small Molecule API 麻豆原创 by Source, 2022-2032, $ mn 45
Table 9. Europe Small Molecule API 麻豆原创: Synthetic API by Drug Type, 2022-2032, $ mn 47
Table 10. Europe Small Molecule API 麻豆原创 by Product Type, 2022-2032, $ mn 52
Table 11. Europe Small Molecule API 麻豆原创: HPAPI by Drug Type, 2022-2032, $ mn 55
Table 12. Europe Small Molecule API 麻豆原创 by Therapeutic Area, 2022-2032, $ mn 58
Table 13. Europe Small Molecule API 麻豆原创 by Application, 2022-2032, $ mn 68
Table 14. Europe Small Molecule API 麻豆原创 by Manufacturer Type, 2022-2032, $ mn 72
Table 15. Europe Small Molecule API 麻豆原创 by Country, 2022-2032, $ mn 80
Table 16. Germany Small Molecule API 麻豆原创 by Product Type, 2022-2032, $ mn 82
Table 17. Germany Small Molecule API 麻豆原创 by Therapeutic Area, 2022-2032, $ mn 82
Table 18. Germany Small Molecule API 麻豆原创 by Manufacturer Type, 2022-2032, $ mn 82
Table 19. U.K. Small Molecule API 麻豆原创 by Product Type, 2022-2032, $ mn 84
Table 20. U.K. Small Molecule API 麻豆原创 by Therapeutic Area, 2022-2032, $ mn 84
Table 21. U.K. Small Molecule API 麻豆原创 by Manufacturer Type, 2022-2032, $ mn 84
Table 22. France Small Molecule API 麻豆原创 by Product Type, 2022-2032, $ mn 86
Table 23. France Small Molecule API 麻豆原创 by Therapeutic Area, 2022-2032, $ mn 86
Table 24. France Small Molecule API 麻豆原创 by Manufacturer Type, 2022-2032, $ mn 86
Table 25. Spain Small Molecule API 麻豆原创 by Product Type, 2022-2032, $ mn 88
Table 26. Spain Small Molecule API 麻豆原创 by Therapeutic Area, 2022-2032, $ mn 88
Table 27. Spain Small Molecule API 麻豆原创 by Manufacturer Type, 2022-2032, $ mn 88
Table 28. Italy Small Molecule API 麻豆原创 by Product Type, 2022-2032, $ mn 90
Table 29. Italy Small Molecule API 麻豆原创 by Therapeutic Area, 2022-2032, $ mn 90
Table 30. Italy Small Molecule API 麻豆原创 by Manufacturer Type, 2022-2032, $ mn 90
Table 31. Russia Small Molecule API 麻豆原创 by Product Type, 2022-2032, $ mn 92
Table 32. Russia Small Molecule API 麻豆原创 by Therapeutic Area, 2022-2032, $ mn 92
Table 33. Russia Small Molecule API 麻豆原创 by Manufacturer Type, 2022-2032, $ mn 92
Table 34. Small Molecule API 麻豆原创 in Rest of Europe by Country, 2022-2032, $ mn 94
Table 35. Aurobindo Pharma Ltd.: Company Snapshot 99
Table 36. Aurobindo Pharma Ltd.: Business Segmentation 100
Table 37. Aurobindo Pharma Ltd.: Product Portfolio 100
Table 38. Cambrex Corporation: Company Snapshot 101
Table 39. Catalent Inc.: Company Snapshot 102
Table 40. Catalent Inc.: Business Segmentation in 2018 102
Table 41. Catalent Inc.: Product Portfolio 103
Table 42. Catalent Inc.: Revenue, 2018-2020, $ million 103
Table 43. Catalent Inc.: Revenue by Region in 2018 104
Table 44. Dr. Reddy's Laboratories: Company Snapshot 105
Table 45. Dr. Reddy's Laboratories: Business Segmentation 105
Table 46. Dr. Reddy's Laboratories: Revenue, 2018-2020, $ bn 106
Table 47. GlaxoSmithKline: Company Snapshot 108
Table 48. GlaxoSmithKline: Business Segmentation 109
Table 49. GlaxoSmithKline: Product Portfolio 110
Table 50. GlaxoSmithKline: Revenue, 2018-2020, $ bn 111
Table 51. Lonza Group: Company Snapshot 112
Table 52. Lonza Group: Business Segmentation in 2018 112
Table 53. Lonza Group: Product Portfolio 113
Table 54. Lonza Group: Revenue by Region in 2018 113
Table 55. Merck & Co., Inc.: Company Snapshot 115
Table 56. Merck & Co., Inc.: Business Segmentation 115
Table 57. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 116
Table 58. Mylan NV: Company Snapshot 117
Table 59. Mylan NV: Revenue, 2017-2019, $ bn 118
Table 60. Novartis International AG: Company Snapshot 119
Table 61. Novartis International AG: Business Segmentation 119
Table 62. Novartis International AG: Revenue, 2017-2019, $ bn 120
Table 63. Pfizer Inc.: Company Snapshot 121
Table 64. Pfizer Inc.: Business Segmentation 122
Table 65. Pfizer Inc.: Product Portfolio 123
Table 66. Pfizer Inc.: Revenue, 2018-2020, $ bn 123
Table 67. Sun Pharmaceutical Industries Limited: Company Snapshot 125
Table 68. Teva Pharmaceutical Industries Ltd.: Company Snapshot 128
Table 69. Teva Pharmaceutical Industries Ltd.: Business Segmentation 129
Table 70. WuXi AppTec Inc.: Company Snapshot 130
List of Figures:
Figure 1. Research Method Flow Chart 12
Figure 2. Bottom-up Approach and Top-down Approach for 麻豆原创 Estimation 15
Figure 3. Europe 麻豆原创 Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 17
Figure 4. Europe Small Molecule API 麻豆原创, 2022-2032, $ mn 20
Figure 5. Impact of COVID-19 on Business 24
Figure 6. Primary Drivers and Impact Factors of Europe Small Molecule API 麻豆原创 30
Figure 7. Primary Restraints and Impact Factors of Europe Small Molecule API 麻豆原创 34
Figure 8. Investment Opportunity Analysis 38
Figure 9. Porter鈥檚 Fiver Forces Analysis of Europe Small Molecule API 麻豆原创 41
Figure 10. Breakdown of Europe Small Molecule API 麻豆原创 by Source, 2022-2032, % of Revenue 46
Figure 11. Europe Addressable 麻豆原创 Cap in 2023-2032 by Source, Value ($ mn) and Share (%) 46
Figure 12. Europe Small Molecule API 麻豆原创 by Source: Synthetic API, 2022-2032, $ mn 47
Figure 13. Europe Small Molecule API 麻豆原创 by Synthetic API: Branded Synthetic API, 2022-2032, $ mn 48
Figure 14. Europe Small Molecule API 麻豆原创 by Synthetic API: Generic Synthetic API, 2022-2032, $ mn 49
Figure 15. Europe Small Molecule API 麻豆原创 by Source: Semi-synthetic API, 2022-2032, $ mn 50
Figure 16. Europe Small Molecule API 麻豆原创 by Source: Natural Origin, 2022-2032, $ mn 51
Figure 17. Breakdown of Europe Small Molecule API 麻豆原创 by Product Type, 2022-2032, % of Sales Revenue 53
Figure 18. Europe Addressable 麻豆原创 Cap in 2023-2032 by Product Type, Value ($ mn) and Share (%) 53
Figure 19. Europe Small Molecule API 麻豆原创 by Product Type: Standard API, 2022-2032, $ mn 54
Figure 20. Europe Small Molecule API 麻豆原创 by Product Type: High Potency API (HPAPI), 2022-2032, $ mn 55
Figure 21. Europe Small Molecule API 麻豆原创 by HPAPI: Branded HPAPI, 2022-2032, $ mn 56
Figure 22. Europe Small Molecule API 麻豆原创 by HPAPI: Generic HPAPI, 2022-2032, $ mn 57
Figure 23. Breakdown of Europe Small Molecule API 麻豆原创 by Therapeutic Area, 2022-2032, % of Sales Revenue 59
Figure 24. Europe Addressable 麻豆原创 Cap in 2023-2032 by Therapeutic Area, Value ($ mn) and Share (%) 59
Figure 25. Europe Small Molecule API 麻豆原创 by Therapeutic Area: Infectious Diseases, 2022-2032, $ mn 60
Figure 26. Europe Small Molecule API 麻豆原创 by Therapeutic Area: Oncology, 2022-2032, $ mn 61
Figure 27. Europe Small Molecule API 麻豆原创 by Therapeutic Area: Ophthalmology, 2022-2032, $ mn 62
Figure 28. Europe Small Molecule API 麻豆原创 by Therapeutic Area: Cardiovascular Disorders, 2022-2032, $ mn 63
Figure 29. Europe Small Molecule API 麻豆原创 by Therapeutic Area: Central Nervous System, 2022-2032, $ mn 64
Figure 30. Europe Small Molecule API 麻豆原创 by Therapeutic Area: Respiratory Disorders, 2022-2032, $ mn 65
Figure 31. Europe Small Molecule API 麻豆原创 by Therapeutic Area: Metabolic Diseases, 2022-2032, $ mn 66
Figure 32. Europe Small Molecule API 麻豆原创 by Therapeutic Area: Other Therapeutic Areas, 2022-2032, $ mn 67
Figure 33. Breakdown of Europe Small Molecule API 麻豆原创 by Application, 2022-2032, % of Revenue 69
Figure 34. Europe Addressable 麻豆原创 Cap in 2023-2032 by Application, Value ($ mn) and Share (%) 69
Figure 35. Europe Small Molecule API 麻豆原创 by Application: Clinical Use, 2022-2032, $ mn 70
Figure 36. Europe Small Molecule API 麻豆原创 by Application: Commercial Use, 2022-2032, $ mn 71
Figure 37. Breakdown of Europe Small Molecule API 麻豆原创 by Manufacturer Type, 2022-2032, % of Revenue 73
Figure 38. Europe Addressable 麻豆原创 Cap in 2023-2032 by Manufacturer Type, Value ($ mn) and Share (%) 73
Figure 39. Europe Small Molecule API 麻豆原创 by Manufacturer Type: Pharmaceutical Companies, 2022-2032, $ mn 74
Figure 40. Breakdown of Europe Small Molecule API In-house Synthesis 麻豆原创 by Region, 2020-2027, % of Revenue 75
Figure 41. Europe Small Molecule API 麻豆原创 by Manufacturer Type: CMOs, 2022-2032, $ mn 76
Figure 42. Breakdown of Europe Small Molecule API Contract Synthesis 麻豆原创 by Region, 2020-2027, % of Revenue 77
Figure 43. Breakdown of European Small Molecule API 麻豆原创 by Country, 2022 and 2032, % of Revenue 79
Figure 44. Contribution to Europe 2023-2032 Cumulative 麻豆原创 by Country, Value ($ mn) and Share (%) 80
Figure 45. Small Molecule API 麻豆原创 in Germany, 2022-2032, $ mn 81
Figure 46. Small Molecule API 麻豆原创 in U.K., 2022-2032, $ mn 83
Figure 47. Small Molecule API 麻豆原创 in France, 2022-2032, $ mn 85
Figure 48. Small Molecule API 麻豆原创 in Spain, 2022-2032, $ mn 87
Figure 49. Small Molecule API 麻豆原创 in Italy, 2022-2032, $ mn 89
Figure 50. Small Molecule API 麻豆原创 in Russia, 2022-2032, $ mn 91
Figure 51. Small Molecule API 麻豆原创 in Rest of Europe, 2022-2032, $ mn 93
Figure 52. Growth Stage of Europe Small Molecule API Industry over the Forecast Period 95
Selected Key Players:
Aurobindo Pharma Ltd.
Cambrex Corporation
Catalent Inc.
Dr. Reddy's Laboratories
GlaxoSmithKline plc
Lonza Group
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Wuxi AppTec Co., Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
听
听
*If Applicable.
